RenovoRx reports 2025 revenue of $1.1M from RenovoCath; net loss $11.2M; cash $13M after $10M financing

RenovoRx, Inc.

FY2025 revenue $1.1M vs $43K in 2024; first full year of RenovoCath commercialization; cost of revenue $327K, gross profit $796K.
Net loss $11.2M ($0.32 diluted EPS) vs $8.8M ($0.40) in 2024; R&D spend $6.3M, SG&A $7.0M.
Phase III TIGeR-PaC trial: 104 patients randomized (target 114), 72 deaths; enrollment completion expected mid-2026, final data 2027.
12 U.S. cancer centers actively using RenovoCath as of Feb 2026; 33 centers in pipeline; $400M peak U.S. TAM for device.
Appointed Mark Voll as CFO in Feb 2026; closed $10M private placement (net $9.2M) on Mar 20, 2026; cash $13M on hand.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RenovoRx, Inc. reported fiscal year ended December 31, 2025 results: revenue $1.1 million.

Period: fiscal year ended December 31, 2025
Revenue: $1.1 million
Result: reported results

Exact text from the filing

For the year ending December 31, 2025, the Company generated $1.1 million in revenue from RenovoCath sales, driven by both new cancer centers adopting the device and repeat orders from existing customers.

View on SEC.gov

Browse all earnings releases →

RenovoRx, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-013653

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.